4 ms·
First, on the article itself. That title is just misleading clickbait. In the same article we go from: > The first 100% effective HIV prevention drug is appro
by nerdjon 1y ago
First, on the article itself. That title is just misleading clickbait.
In the same article we go from:
> The first 100% effective HIV prevention drug is approved and going global
to a couple paragaphs in:
> sold under the brand name Yeztugo – a class of drugs known as capsid inhibitors, which provide almost 100% protection against HIV infection
To a little bit later:
> The pre-exposure prophylaxis (PrEP) provides HIV-negative individuals around 99% protection from contracting the devastating virus through sex.
So... that is terrible writing about a topic like this.
From what I have seen there is no difference in effectiveness of this drug compared to the pills we already have if you actually take them properly.
I would love to be proven wrong, but this seems basically the same efficacy numbers we see for truvada and descovy.
That doesnt mean it is not still valuable, properly taking the pill every day is a huge component of that. I know I plan on looking at the shot personally.
But the reporting on this article is extremely shady.
- cguess 1y agoThe difference is it's twice a year injection, not daily or monthly pills. For many at-risk populations (unhoused, people living in the rural developing world) taking a pill once a day, or even monthly, much less making you can refill your prescription is insanely difficult.
- duskwuff 1y agoThere's an ugly social aspect to it, too. In South Africa, for a woman who is in a relationship to take PrEP is often seen as an admission of her infidelity. https://www.researchgate.net/publication/262227835_Concerns_about_partner_infidelity_are_a_barrier_to_adoption_of_HIV-prevention_strategies_among_young_South_African_couples https://www.researchgate.net/publication/262227835_Concerns_...
- croemer 1y agoYeah, terrible article. This one should be the link target instead: https://www.nbcnews.com/news/amp/rcna208387 https://www.nbcnews.com/news/amp/rcna208387